GlobeNewswire: Aegerion Pharmaceuticals, Inc. Contains the last 10 of 235 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T05:40:46ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2016/11/29/893578/0/en/Aegerion-Pharmaceuticals-Inc-and-QLT-Inc-Complete-Merger-Transaction-QLT-to-Change-Name-to-Novelion-Therapeutics-Inc.html?f=22&fvtc=4&fvtv=13010Aegerion Pharmaceuticals, Inc. and QLT Inc. Complete Merger Transaction; QLT to Change Name to Novelion Therapeutics Inc.2016-11-29T17:09:58Z<![CDATA[-- Transaction creates strong, diversified rare-disease focused portfolio-- Novelion Therapeutics completes concurrent financing of approximately $22 million -- Company to host conference call today at 4:30 p.m. ET]]>https://www.globenewswire.com/news-release/2016/11/17/891153/0/en/Aegerion-Pharmaceuticals-JUXTAPID-lomitapide-Capsules-for-the-Treatment-of-Homozygous-Familial-Hypercholesterolemia-HoFH-Receives-Pricing-Authorization-in-Japan.html?f=22&fvtc=4&fvtv=13010Aegerion Pharmaceuticals’ JUXTAPID® (lomitapide) Capsules for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) Receives Pricing Authorization in Japan2016-11-17T21:15:00Z<![CDATA[CAMBRIDGE, Mass., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that Japan’s Ministry of Health, Labor & Welfare (MHLW) has approved pricing of JUXTAPID in Japan. The pricing authorization follows Japanese regulatory approval of Juxtapid for the treatment of homozygous familial hypercholesterolemia (HoFH) on September 28, 2016.]]>https://www.globenewswire.com/news-release/2016/11/03/886607/0/en/Aegerion-Pharmaceuticals-Announces-Third-Quarter-2016-Financial-Results.html?f=22&fvtc=4&fvtv=13010Aegerion Pharmaceuticals Announces Third Quarter 2016 Financial Results2016-11-03T20:05:00Z<![CDATA[Company records $35.4 million in total net product sales Company records $35.4 million in total net product sales]]>https://www.globenewswire.com/news-release/2016/09/28/875439/0/en/Aegerion-Pharmaceuticals-JUXTAPID-lomitapide-Capsules-Approved-in-Japan-for-the-Treatment-of-Homozygous-Familial-Hypercholesterolemia-HoFH.html?f=22&fvtc=4&fvtv=13010Aegerion Pharmaceuticals’ JUXTAPID® (lomitapide) Capsules Approved in Japan for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)2016-09-28T20:05:00Z<![CDATA[CAMBRIDGE, Mass., Sept. 28, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that Japan’s Ministry of Health, Labor & Welfare (MHLW) has approved JUXTAPID for patients with homozygous familial hypercholesterolemia (HoFH).]]>https://www.globenewswire.com/news-release/2016/09/24/874281/0/en/Aegerion-Pharmaceuticals-Observes-Familial-Hypercholesterolemia-Awareness-Day.html?f=22&fvtc=4&fvtv=13010Aegerion Pharmaceuticals Observes Familial Hypercholesterolemia Awareness Day2016-09-24T12:00:00Z<![CDATA[CAMBRIDGE, Mass., Sept. 24, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating rare diseases, announced today its observance of The FH Foundation’s annual Familial Hypercholesterolemia (FH) Awareness Day.]]>https://www.globenewswire.com/news-release/2016/09/20/873164/0/en/Aegerion-Pharmaceuticals-Appoints-Remi-Menes-as-Chief-Commercial-Officer.html?f=22&fvtc=4&fvtv=13010Aegerion Pharmaceuticals Appoints Remi Menes as Chief Commercial Officer2016-09-20T12:50:00Z<![CDATA[CAMBRIDGE, Mass., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced the appointment of Remi A. Menes as chief commercial officer, effective immediately.]]>https://www.globenewswire.com/news-release/2016/08/09/862946/0/en/Aegerion-Pharmaceuticals-Announces-Second-Quarter-2016-Financial-Results.html?f=22&fvtc=4&fvtv=13010Aegerion Pharmaceuticals Announces Second Quarter 2016 Financial Results2016-08-09T20:10:46Z<![CDATA[-- Company records $44.5 million in total net product sales ---- Company reiterates 2016 total net product sales guidance of between $130 and $150 million --CAMBRIDGE, Mass., Aug. 09, 2016 (GLOBE NEWSWIRE) --  Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced its financial results and business update for the second quarter of 2016.]]>https://www.globenewswire.com/news-release/2016/07/20/857622/0/en/Aegerion-Pharmaceuticals-Announces-Cost-Reduction-Plans.html?f=22&fvtc=4&fvtv=13010Aegerion Pharmaceuticals Announces Cost Reduction Plans2016-07-20T20:02:00Z<![CDATA[Company announces revision to lomitapide ex-U.S. strategy and reduction in global workforce Company announces revision to lomitapide ex-U.S. strategy and reduction in global workforce]]>https://www.globenewswire.com/news-release/2016/06/15/848714/0/en/Aegerion-Pharmaceuticals-and-QLT-Inc-Agree-to-Strategic-Merger.html?f=22&fvtc=4&fvtv=13010Aegerion Pharmaceuticals and QLT Inc. Agree to Strategic Merger 2016-06-15T11:00:00Z<![CDATA[--Strategic Merger Creates Well-Capitalized, Global Biopharmaceutical Organization with Diverse Portfolio of Two Commercialized Rare Disease Programs and a Phase 3 Ready Ultra-Orphan Development Program Addressing Significant Unmet Medical Need----Broad-Based Investor Syndicate to Vote in Favor of the Merger and Provide Concurrent Financing of Approximately $22 Million--]]>https://www.globenewswire.com/news-release/2016/06/07/846827/0/en/Aegerion-Pharmaceuticals-Grants-Stock-Options-Under-Inducement-Program.html?f=22&fvtc=4&fvtv=13010Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program2016-06-07T20:45:00Z<![CDATA[CAMBRIDGE, Mass., June 07, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that on June 1, 2016, Aegerion granted stock options to purchase an aggregate of 10,958 shares of common stock to six new employees under the inducement stock option program described below. Each stock option has an exercise price per share equal to $1.93, the closing price of Aegerion’s common stock on the grant date; vests 25% on the first anniversary of the date of grant with the remaining 75% to vest in monthly installments over the three years thereafter; has a ten year term; and is subject to the terms and conditions of Aegerion’s Inducement Award Stock Option Plan, and the terms and conditions of a stock option agreement covering the grant.]]>